| 1 | 2023 quest pharmatech provides | | | | | | | 3 | 0.55% |
| 2 | immunotherapy asset transfer between | | | | | | | 3 | 0.55% |
| 3 | to immunotherapy asset transfer | | | | | | | 3 | 0.55% |
| 4 | oncoquest inc and oncoquest | | | | | | | 2 | 0.37% |
| 5 | provides update to immunotherapy | | | | | | | 2 | 0.37% |
| 6 | 2021 quest pharmatech announces | | | | | | | 2 | 0.37% |
| 7 | provides corporate update press | | | | | | | 2 | 0.37% |
| 8 | in frontline ovarian cancer | | | | | | | 2 | 0.37% |
| 9 | quest pharmatech provides corporate | | | | | | | 2 | 0.37% |
| 10 | transfer between oncoquest inc | | | | | | | 2 | 0.37% |
| 11 | 2021 quest provides update | | | | | | | 2 | 0.37% |
| 12 | pharmatech provides corporate update | | | | | | | 2 | 0.37% |
| 13 | financialmda contact us home | | | | | | | 2 | 0.37% |
| 14 | asset transfer between oncoquest | | | | | | | 2 | 0.37% |
| 15 | truncated muc16 officers and | | | | | | | 2 | 0.37% |
| 16 | muc16 officers and directors | | | | | | | 2 | 0.37% |
| 17 | officers and directors investor | | | | | | | 2 | 0.37% |
| 18 | company’s lead investigational drug | | | | | | | 2 | 0.37% |
| 19 | and oncoquest pharmaceuticals inc | | | | | | | 2 | 0.37% |
| 20 | update to immunotherapy asset | | | | | | | 2 | 0.37% |
| 21 | releases financialmda contact us | | | | | | | 2 | 0.37% |
| 22 | in combination therapy for | | | | | | | 1 | 0.18% |
| 23 | cancer july 7 2021 | | | | | | | 1 | 0.18% |
| 24 | ovarian cancer july 7 | | | | | | | 1 | 0.18% |
| 25 | recurrent ovarian cancer july | | | | | | | 1 | 0.18% |
| 26 | for the treatment of | | | | | | | 1 | 0.18% |
| 27 | therapy for the treatment | | | | | | | 1 | 0.18% |
| 28 | oncoquest pharmaceuticals inc announces | | | | | | | 1 | 0.18% |
| 29 | combination therapy for the | | | | | | | 1 | 0.18% |
| 30 | oregovomab in combination therapy | | | | | | | 1 | 0.18% |
| 31 | first patient enrolled in | | | | | | | 1 | 0.18% |
| 32 | of oregovomab in combination | | | | | | | 1 | 0.18% |
| 33 | trials of oregovomab in | | | | | | | 1 | 0.18% |
| 34 | 2021 oncoquest pharmaceuticals inc | | | | | | | 1 | 0.18% |
| 35 | of two investigator initiated | | | | | | | 1 | 0.18% |
| 36 | each of two investigator | | | | | | | 1 | 0.18% |
| 37 | in each of two | | | | | | | 1 | 0.18% |
| 38 | enrolled in each of | | | | | | | 1 | 0.18% |
| 39 | patient enrolled in each | | | | | | | 1 | 0.18% |
| 40 | two investigator initiated clinical | | | | | | | 1 | 0.18% |